1	NVAC Vaccine Safety Working Group Daniel Salmon Vaccine Safety Specialist National Vaccine Program Office Department of Health and Human Services
2	Working Group Charge 1 Undertake and coordinate a scientific review of the draft ISO research agenda. Advise on: Content of ISO draft research agenda (e.g., are the topics on the agenda appropriate? Should other topics be included?) Prioritization of research topics Possible scientific barriers to implementing the research agenda and suggestions for addressing them
3	Working Group Members
4	Working Group Members, cont.
5	Methods Information gathering Content review by subgroups Drafting of recommendations Internal peer review Revision Currently under consideration by NVAC and soliciting public input on the draft report Planned NVAC vote June 2, 2009
6	Public Engagement Meetings facilitated by the Keystone Center Three community meetings (Birmingham AL, Ashland OR, Indianapolis IN) Writing Group meeting in Salt Lake City UT Stakeholder meeting in Washington DC Two formal solicitations for written public comments
7
8	Prioritization of Research Topics
9	Overarching Issues Constraints of looking at draft ISO Scientific Agenda in isolation and need to include other partners There should be clear emphasis on prevention, and when prevention is not possible, amelioration of vaccine adverse events
10	General Recommendations The Working Group recommends ISO develop the research topic sections of Vaccines and Vaccination Practices, Special Populations, and Clinical Outcomes to consist of testable research questions that can be prioritized. The Working Group recommends periodic external review of VSD and CISA research and the ISO Scientific Agenda more broadly. ISO should regularly engage the public and stakeholders as ISO conducts research, interprets the findings from their studies, and revises their research agenda.
11	General Recommendations ISO should perform case studies of past decision making processes related to vaccine safety issues to identify lessons learned regarding the use of scientific data in decision making. To prepare for mass vaccination use of vaccines not traditionally given to the civilian population, ISO should investigate in advance approaches to safety monitoring, including the extent to which they would be used off-label or in new populations.
12	General Recommendations To better understand the biological mechanisms responsible for adverse events following immunization, ISO should coordinate with other agencies to support basic research and CISA should conduct clinical research on the pathophysiologic basis of adverse events. The Working Group endorses the Writing Group’s recommendation for an external expert committee, such as the IOM, with broad methodological, design, and ethical expertise to consider “strengths and weaknesses, ethical issues and feasibility, including timelines and cost of various study designs to examine outcomes in unvaccinated, vaccine delayed and vaccinated children
13	General Recommendations ISO studies should be designed and adequately powered to assess the role of differences in race/ethnicity and gender when appropriate. ISO should have an active role in risk communications research. ISO should identify and evaluate ways to (1) increase the number of severe events that are reported to VAERS; and (2) improve the quality and completeness of the reports received.
14	Capacity Recommendations ISO should evaluate approaches to follow up individuals reported to VAERS with rare or unusual adverse events for further study, including the collection of biological specimens, when appropriate. The ISO Scientific Agenda should specify the laboratory capacity needed for vaccine safety research and identify potential collaborations with other Federal agencies or private entities for those areas where ISO lacks capacity. For the laboratory capacity that CDC/ISO currently possesses, ISO should request input from external experts to advise on the ongoing work and development of new laboratory methodologies.
15	Capacity Recommendations ISO should study molecular immune responses to vaccinations, including common adverse events such as fever or rash, as subclinical correlates that might predict severe adverse events. ISO should create an expert advisory group on genomics and vaccine safety to assist with developing a focused genomics research agenda and protocol development. ISO should focus Brighton Collaboration research efforts on the adequacy of the case definitions and their usefulness in ongoing safety research conducted by VSD and other groups.
16	Capacity Recommendations The Working Group recommends ISO create a single written guide dedicated to comprehensive clinical guidance, including identification, reporting, and treatment, for vaccine adverse events. ISO should include the vaccination of children with mitochondrial disease, mitochondrial dysfunction, and other metabolic diseases as a priority scientific area for research to develop clinical guidance.
17	Research Recommendations
18	Priorities: Low
19
20
21	Priorities: High